Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
89.82
-0.96 (-1.06%)
At close: Oct 12, 2026, 4:00 PM EDT
89.08
-0.74 (-0.83%)
After-hours: Oct 12, 2026, 4:05 PM EDT
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $71.26M in the quarter ending June 30, 2026, with 46.91% growth. This brings the company's revenue in the last twelve months to $239.92M, up 53.51% year-over-year. In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth. That makes Rhythm Pharmaceuticals the 16,119th largest company in the world by revenue and 2,765th in the United States.
Revenue (ttm)
$239.92M
Revenue Growth
+53.51%
P/S Ratio
26.12
Revenue / Employee
$579,512
Employees
414
Market Cap
6.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Mirum Pharmaceuticals | 618.07M |
| Iovance Biotherapeutics | 324.97M |
| Ligand Pharmaceuticals | 290.54M |
| CG Oncology | 6.23M |
RYTM News
- 20 days ago - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity - GlobeNewsWire
- 27 days ago - Rhythm Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Rhythm Pharmaceuticals Slides: Corporate presentation - Filings
- 7 weeks ago - Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - GlobeNewsWire
- 1 month ago - Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts